Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases

BACKGROUND: Type 2 inflammation is common in numerous atopic/allergic diseases and can be identified by elevated biomarker levels. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin‐4 and interleukin‐13, key and central drivers of type 2 inflammation....

Descripción completa

Detalles Bibliográficos
Autores principales: Hamilton, Jennifer D., Harel, Sivan, Swanson, Brian N., Brian, William, Chen, Zhen, Rice, Megan S., Amin, Nikhil, Ardeleanu, Marius, Radin, Allen, Shumel, Brad, Ruddy, Marcella, Patel, Naimish, Pirozzi, Gianluca, Mannent, Leda, Graham, Neil M. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362102/
https://www.ncbi.nlm.nih.gov/pubmed/34037993
http://dx.doi.org/10.1111/cea.13954

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362102/
https://www.ncbi.nlm.nih.gov/pubmed/34037993
http://dx.doi.org/10.1111/cea.13954

Ejemplares similares